Quotes 5-day view Delayed Nyse
01/11/2021
01/12/2021
01/13/2021
01/14/2021
01/15/2021
Date
185.94(c)
178.8(c)
185.5(c)
186.69(c)
190.77(c)
Last
11 402 288
7 179 275
7 303 875
4 413 184
6 553 224
Volume
+11.74% -3.84% +3.75% +0.64% +2.19% Change
Sales 2020
24 408 M - -
Net income 2020
5 802 M - -
Net Debt 2020
11 301 M - -
P/E ratio 2020
30,0x
Yield 2020
1,56%
Sales 2021
27 490 M - -
Net income 2021
7 055 M - -
Net Debt 2021
9 258 M - -
P/E ratio 2021
24,6x
Yield 2021
1,75%
Capitalization
173 B 173 B -
EV / Sales 2020
7,55x
EV / Sales 2021
6,63x
Nbr of Employees
33 625
Free-Float
99,8%
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both...
Notations Surperformance© of Eli Lilly and Company
Trading Rating : Investor Rating :
All news about ELI LILLY AND COMPANY
News in other languages on ELI LILLY AND COMPANY
Analyst Recommendations on ELI LILLY AND COMPANY
Eli Lilly to buy gene therapy developer Prevail in about $1 bln deal
Chart ELI LILLY AND COMPANY
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ELI LILLY AND COMPANY
Short Term Mid-Term Long Term Trends Bullish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
20
Average target price
181,58 $
Last Close Price
190,77 $
Spread / Highest target
19,0%
Spread / Average Target
-4,82%
Spread / Lowest Target
-37,1%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
